Pharmaceuticals
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced ...
2026-03-09 16:32
6161
Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK)announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core inve...
2026-03-09 14:28
4639
CARsgen Therapeutics Announces 2025 Annual Results
SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights * Cash and cash equivalents were around RMB1,123 million as of Decemb...
2026-03-06 20:03
9958
Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previou...
2026-03-06 18:53
6471
Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online
Titled "The Potential of Fasting and Diet in the Future of Medicine" Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage ...
2026-03-05 22:28
3928
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent or metasta...
2026-03-05 10:26
7663
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
* Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer * Novel combination therapy will be studied as part of the Phase II adaptive pl...
2026-03-04 21:52
7656
Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
HOUSTON, March 3, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sin...
2026-03-04 09:53
6409
Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery
Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks while running entirely on private pharmaceutical infrastructure CAMBRIDGE, Mass., March 3, 2026 /PRNewswire/ -- Insilico Medicine and Liquid AI today announced a partnership that creates lightweigh...
2026-03-03 22:25
6199
The largest pharma show in Asia makes its return to Shanghai this June 2026
SHANGHAI, March 2, 2026 /PRNewswire/ -- CPHI & PMEC China 2026 is set to take place from 16 to18 June 2026 at the Shanghai New International Expo Centre (SNIEC), building on its extremely successful run over the last few years. As the world's premier destination for pharmaceutical ingredients and...
2026-03-03 10:15
3785
XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
SUZHOU, China, March 2, 2026 /PRNewswire/ -- In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart)announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed, off-the-shelf, allogeneic, uni...
2026-03-02 22:10
4373
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®
PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly announced positive topline results from a Phase II clinical trial of it...
2026-03-02 22:00
4323
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare an...
2026-03-02 22:00
4988
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SAN FRANCISCO and SUZHOU, China, March 1, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...
2026-03-02 08:00
6537
Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) on WuXi XDC's proprietary WuXiTecan...
2026-02-27 15:00
5061
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself,me...
2026-02-27 08:00
6103
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...
2026-02-27 04:34
7387
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
* SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines inEurope to improve vaccine performance and access. * Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic influenza threats. INCHEON, South Korea,...
2026-02-26 21:00
7223
Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
SHANGHAI, Feb. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio"), a biotech company powered by super-trillion-molecule libraries and AI-driven technologies, today announced the completion of a significant equity restructuring. The shares previously held by Hai...
2026-02-24 22:00
5936
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. andChina. Concurrently, the company's "AI + Chemical Induction" platform saw its...
2026-02-23 21:00
4996
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 304 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 300 media titles]
2026-05-19 23:59
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 287 media titles]
2026-05-18 15:30
Amity's Singapore-Headquartered AI Research Center Wins Gold at Taiwan's 2026 Best AI Awards
[Picked up by 282 media titles]
2026-05-13 08:00
Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
7393
